Work

Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.3056

Authors: Tyler J. Moss, Jordi Rodon Ahnert, Holly D. Oakley, Michael Kahle, Daniel D. Karp, Shubham Pant, Jeena Jacob, Victoria M. Raymond, Richard B. Lanman, Lawrence Kwong, Mark Routbort, Nital Soni, Jerry Huang, Milind M. Javle, Funda Meric-Bernstam

Institutions: The University of Texas MD Anderson Cancer Center, Guardant (United States), Taiho Oncology (United States)

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947477015

Cites:

Cited by: 6

Related to: 10